Q-omics provides the consensus-scored RPL23AP53 profile across patient tissues and cancer cell-line models. RPL23AP53 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RPL23AP53 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, RPL23AP53 RNA expression shows 19,161 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, LIHC, and UVM as cancer lineages where RPL23AP53 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL23AP53 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL23AP53 survival associations across molecular data types. RPL23AP53 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL23AP53 RNA expression–survival associations across cancer types. High RPL23AP53 expression shows unfavorable associations in BLCA, LIHC, KICH and THCA, but favorable associations in HNSC and KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RPL23AP53 RNA expression.
This table summarizes RPL23AP53 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL23AP53. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL23AP53 shows lower tumor expression in LUSC, KICH, LUAD and BRCA and higher tumor expression in LIHC and KIRP. The LIHC box plot shows higher RPL23AP53 RNA expression in tumor versus normal tissue (log2 FC = +0.530, t-test p < 0.001).
This table shows molecular features associated with RPL23AP53 in patient tissues and cancer cell lines. In patient samples, RPL23AP53 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RPL23AP53 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
